Nephropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:19 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Nephropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Kidney Contenders https://clinicaltrials.eu/organisation/kidney-contenders/ Tue, 02 Jun 2026 10:00:16 +0000 https://clinicaltrials.eu/organisation/kidney-contenders/ Kidney Contenders is an educational initiative dedicated to kidney health and raising awareness about chronic kidney disease (CKD). Their activities are mainly directed at people living with kidney conditions, dialysis patients, and anyone who wants to take better care of their health through prevention, proper hydration, and healthy nutrition. An important part of their mission is connecting patients, caregivers, and professionals through easily accessible educational content.

]]> A study to evaluate the efficacy and safety of obinutuzumab compared to prednisolone in adults with newly onset minimal change disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-compared-to-prednisolone-in-adults-with-newly-onset-minimal-change-disease/ Wed, 29 Apr 2026 15:10:06 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuzumab-compared-to-prednisolone-in-adults-with-newly-onset-minimal-change-disease/ This study aims to evaluate the effectiveness and safety of obinutuzumab in adults with newly diagnosed minimal change disease, a type of kidney disease. This condition involves damage to the filtering units of the kidney, which can lead to protein leaking into the urine. Participants in the study will receive either the study drug or a standard treatment consisting of prednisolone or prednisone, which are types of glucocorticoids used to reduce inflammation. Other medications that may be used as background therapy include rituximab and tacrolimus.

The study involves comparing the performance of obinutuzumab, which is given through an intravenous infusion, against the standard oral medication regimen. The standard treatment involves a gradual reduction of the medication dose over 24 weeks. Researchers will observe how many people achieve remission, which is a state where the signs and symptoms of the disease decrease or disappear, and how long they stay in this state without the disease returning.

During the study, various factors will be monitored, such as changes in kidney function and protein levels in the urine. The total duration of observation for participants is expected to last up to 52 weeks. This period allows for the assessment of how well the treatments work to manage the minimal change disease and to monitor for any potential side effects or changes in the body’s ability to fight infections.

]]> A Study of ALXN1920 Compared to Placebo in Adults with Primary Membranous Nephropathy at High Risk for Disease Progression https://clinicaltrials.eu/trial/a-study-of-alxn1920-compared-to-placebo-in-adults-with-primary-membranous-nephropathy-at-high-risk-for-disease-progression/ Wed, 29 Apr 2026 15:07:53 +0000 https://clinicaltrials.eu/trial/a-study-of-alxn1920-compared-to-placebo-in-adults-with-primary-membranous-nephropathy-at-high-risk-for-disease-progression/ This study is looking at Primary Membranous Nephropathy, which is a kidney disease that causes damage to the filtering units of the kidneys, leading to protein leaking into the urine. The study will test a medicine called ALXN1920, which is also known by the code name TPP-3621. Some people in the study will receive ALXN1920 while others will receive placebo. The medicine will be given as an injection under the skin. The purpose of the study is to see how well ALXN1920 works compared to placebo in reducing the amount of protein in the urine of people with this kidney disease who are at high risk for the disease getting worse.

People taking part in this study will be adults between 18 and 75 years old who have been diagnosed with Primary Membranous Nephropathy through a positive blood test for a specific antibody called anti-PLA2R antibody. They will need to have high levels of protein in their urine despite being treated with standard blood pressure medicines for at least eight weeks. During the study, participants will continue taking their usual kidney disease treatments along with the study medicine or placebo. The study will last up to 26 weeks, and doctors will regularly check the amount of protein in the urine, blood test results, and overall health of the participants.

Throughout the study, doctors will measure changes in protein levels in the urine, blood albumin levels, which is a protein that can be low in people with this kidney disease, and levels of the anti-PLA2R antibody in the blood. They will also count certain immune cells called CD20+ B cells in the blood and check various markers in the urine and blood. The study team will monitor for any side effects and measure how much of the study medicine is in the body over time. Additionally, they will check if the body develops any immune response to the study medicine.

]]> Study on Colchicine and Opium for Preventing Heart and Kidney Issues in Patients with Moderate Chronic Kidney Disease https://clinicaltrials.eu/trial/study-on-colchicine-and-opium-for-preventing-heart-and-kidney-issues-in-patients-with-moderate-chronic-kidney-disease/ Wed, 29 Apr 2026 14:30:06 +0000 https://clinicaltrials.eu/trial/study-on-colchicine-and-opium-for-preventing-heart-and-kidney-issues-in-patients-with-moderate-chronic-kidney-disease/ This clinical trial is focused on studying the effects of a medication called colchicine in patients with chronic kidney disease. Chronic kidney disease is a condition where the kidneys gradually lose their ability to filter waste from the blood. The study aims to see if taking a low dose of colchicine daily can help prevent further heart and blood vessel problems, as well as slow down the progression of kidney disease in these patients.

Participants in the study will receive either colchicine or a placebo. The study will monitor the occurrence of heart-related events such as heart attacks, strokes, and other issues that might require hospitalization or surgery. It will also look at how the kidneys are functioning over time, checking for any significant changes in kidney health. The study will last for a period of time, during which participants will be regularly assessed to track their health and any changes that occur.

The goal is to determine if colchicine can be beneficial in reducing the risk of serious heart and kidney problems in people with moderate chronic kidney disease. This research could provide valuable insights into new ways to manage and treat this condition, potentially improving the quality of life for those affected.

]]> Study on the Effects of Povetacicept for Adults with IgA Nephropathy https://clinicaltrials.eu/trial/study-on-the-effects-of-povetacicept-for-adults-with-iga-nephropathy/ Wed, 29 Apr 2026 14:22:28 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-povetacicept-for-adults-with-iga-nephropathy/ This clinical trial is focused on studying a kidney disease called Immunoglobulin A Nephropathy (IgAN). This condition affects the kidneys and can lead to kidney damage over time. The study will test a treatment called Povetacicept Injection, which is given as a solution for injection under the skin. The purpose of the study is to see how effective Povetacicept is in reducing the amount of protein in the urine and in preserving kidney function compared to a placebo.

Participants in the study will receive either the Povetacicept Injection or a placebo. The study will last for a total of 104 weeks, which is about two years. During this time, participants will have regular check-ups to monitor their kidney function and the amount of protein in their urine. The study aims to see if Povetacicept can help slow down the progression of kidney disease in people with IgAN.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how well the treatment is working. The results of this study could provide valuable insights into new treatment options for people living with Immunoglobulin A Nephropathy.

]]>